(Q35120940)

6 August 2017

Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans (English)

1 reference

6 August 2017

1 reference

1 reference

Soul-Lawton J

1

1 reference

6 August 2017

Seaber E

2

1 reference

6 August 2017

On N

3

1 reference

6 August 2017

Wootton R

4

1 reference

6 August 2017

Rolan P

5

1 reference

6 August 2017

Posner J

6

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 December 1995

1 reference

Antimicrobial Agents and Chemotherapy

6 August 2017

1 reference

6 August 2017

39

1 reference

6 August 2017

2759-2764

1 reference

6 August 2017

12

1 reference

Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers

6 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=163025

Metabolic disposition of the acyclovir prodrug valaciclovir in the rat.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=163025

Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=163025

Disposition of intravenous radioactive acyclovir

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=163025

Pharmacokinetics of acyclovir after intravenous and oral administration.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=163025

Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=163025

Antiviral effect of oligo(nucleoside methylphosphonates) complementary to the herpes simplex virus type 1 immediate early mRNAs 4 and 5.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=163025

Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=163025

Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=163025

A sensitive radioimmunoassay for the antiviral agent BW248U [9-(2-hydroxyethoxymethyl)guanine]

27 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/8593015

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/8593015

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A Randomized, Placebo-Controlled Trial of Oral Acyclovir for the Prevention of Cytomegalovirus Disease in Recipients of Renal Allografts

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/8593015

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1128/AAC.39.12.2759

1 reference

6 August 2017

1 reference

6 August 2017

1 reference